Adrienne D. Cox
Affiliations: | Genetics & Molecular Biology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Genetics, Molecular BiologyGoogle:
"Adrienne Cox"Children
Sign in to add trainee| Theresa M. Grana | grad student | 2003 | UNC Chapel Hill |
| Patricia J. Keller | grad student | 2005 | UNC Chapel Hill |
| Anastacia C. Berzat | grad student | 2006 | UNC Chapel Hill |
| Donita C. Brady | grad student | 2008 | UNC Chapel Hill |
| Vanessa Gonzalez-Perez | grad student | 2009 | UNC Chapel Hill |
| Jamie K. Alan | grad student | 2010 | UNC Chapel Hill |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Klomp JA, Klomp JE, Stalnecker CA, et al. (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science (New York, N.Y.). 384: eadk0775 |
| Klomp JE, Diehl JN, Klomp JA, et al. (2024) Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. Science (New York, N.Y.). 384: eadk0850 |
| Schaefer A, Hodge RG, Zhang H, et al. (2023) RHOA drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling. Science Signaling. 16: eadg5289 |
| Goodwin CM, Waters AM, Klomp JE, et al. (2022) Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. Cancer Research |
| Diehl JN, Klomp JE, Snare KR, et al. (2021) The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. The Journal of Biological Chemistry. 101335 |
| Cox AD, Der CJ. (2021) Filling in the GAPs in understanding RAS. Science (New York, N.Y.). 374: 152-153 |
| Pedone KH, González-Pérez V, Leopold LE, et al. (2021) Engineering threshold-based selection systems. G3 (Bethesda, Md.). 11 |
| Ozkan-Dagliyan I, Diehl JN, George SD, et al. (2020) Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports. 31: 107764 |
| Javaid S, Waters AM, Nguyen VV, et al. (2020) Abstract B40: Role of mutant HRAS in growth and drug sensitivity of head and neck squamous cell cancers (HNSCC) Molecular Cancer Research. 18 |
| Papke B, Swearingen AEDV, Feng AY, et al. (2020) Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA Molecular Cancer Research. 18 |